Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.

Affiliation

Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, 50 Staniford Street, Suite 580, Boston, MA 02114, USA. Electronic address: [Email]

Abstract

Residual cognitive symptoms in major depressive disorder (MDD) are common, yet poorly investigated. We explored the effectiveness of vortioxetine as adjunctive treatment to selective serotonin reuptake inhibitors (SSRI) and as monotherapy versus continued SSRI, in patients with MDD who achieved full or partial remission with SSRI, but report residual cognitive symptoms.

Keywords

Adjunctive treatment,Clinical trials,Residual cognitive symptoms,SSRIs,Vortioxetine,major depressive disorder,

OUR Recent Articles